Indivior to Report First Quarter 2026 Financial Results

Pharmaceutical company to host webcast on April 30th

Apr. 9, 2026 at 11:19am

Got story updates? Submit your updates here. ›

A high-end, photorealistic studio still-life photograph featuring a stack of pharmaceutical pill bottles and syringes arranged elegantly on a clean, monochromatic seamless background, conceptually representing Indivior's role in the opioid crisis.Indivior's financial results and strategic updates offer insight into the company's role in the ongoing battle against the opioid crisis.Richmond Today

Indivior Pharmaceuticals, Inc. announced that it will report its first quarter 2026 financial results on Thursday, April 30, 2026, at 7:00 a.m. U.S. EDT. Following the release of the financial results, the company's leadership team will host a presentation via live webcast at 8:00 a.m. U.S. EDT.

Why it matters

As a leader in long-acting injectable treatments for opioid use disorder (OUD), Indivior's financial performance and strategic updates are closely watched by investors and the broader pharmaceutical industry.

The details

Indivior will provide access to the live webcast presentation through its company website. Participants can also access the presentation telephonically by registering through a provided link. A replay of the presentation will be available on Indivior's website after the event.

  • Indivior will report its first quarter 2026 financial results on Thursday, April 30, 2026, at 7:00 a.m. U.S. EDT.
  • Indivior will host a live webcast presentation at 8:00 a.m. U.S. EDT on April 30, 2026.

The players

Indivior Pharmaceuticals, Inc.

A pharmaceutical company that is the leader in long-acting injectable treatments for opioid use disorder (OUD).

Joe Ciaffoni

Chief Executive Officer of Indivior Pharmaceuticals, Inc.

Got photos? Submit your photos here. ›

The takeaway

Indivior's financial results and strategic updates are closely watched by the pharmaceutical industry and investors, as the company is a leader in treatments for the ongoing opioid crisis.